Real-world breast cancer treatment patterns and guideline-concordant treatment completion among Malawian women

被引:0
|
作者
Morgan, Jennifer [1 ]
Elmore, Shekinah [2 ]
Zuze, Takondwa [3 ]
Simwinga, Lusayo [3 ]
Nyasosela, Richard [4 ]
Makondi, Precious [4 ]
Manda, Agnes [3 ]
Kajombo, Chifundo [4 ]
Charles, Anthony [5 ]
Carey, Lisa A. [2 ]
Mulenga, Maurice [3 ]
Reeder-Hayes, Katherine [2 ]
Tomoka, Tamiwe [3 ,6 ]
机构
[1] Univ Minnesota, Dept Med, 516 Delaware St SE,PWB 14-148, Minneapolis, MN 55455 USA
[2] Univ North Carolina, Lineberger Canc Ctr, Chapel Hill, NC USA
[3] Univ North Carolina Project Malawi, Lilongwe, Malawi
[4] Kamuzu Cent Hosp, Lilongwe, Malawi
[5] Univ North Carolina, Chapel Hill, NC USA
[6] Kamuzu Univ Hlth Sci, Blantyre, Malawi
关键词
Breast cancer; Treatment; Malawi; SUB-SAHARAN AFRICA; TRASTUZUMAB; SURVIVAL; THERAPY; COHORT; STAGE;
D O I
10.1186/s12905-025-03667-6
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
PurposeIn Sub-Saharan Africa (SSA), resource-stratified guidelines for breast cancer treatment are increasingly recommended, but treatment receipt and outcomes according to these guidelines are underreported. Here, we describe breast cancer treatment patterns by stage and curative-intent guideline-concordant treatment (GCT) receipt among Malawian women.MethodsA prospective cohort of breast cancer patients were enrolled from December 2016 to October 2018 at Kamuzu Central Hospital with an assessment of demographics, stage, and treatment received, including neoadjuvant (NAC), adjuvant (AdC) and palliative chemotherapy and breast surgery. Curative-intent GCT was defined as having completed breast surgery and at least 4 cycles of chemotherapy. Overall survival (OS) was calculated using Kaplan Meier methods and odds ratios using logistic regression.Results91 patients were included, of whom 13 (14%) presented as stage II, 54 (59%) as stage III, and 24 (26%) as stage IV. Curative treatment was recommended for 65 of 91 (71%) patients, of whom 47 (72%) were initiated on NAC, 14 (22%) on upfront breast surgery, and 4 (6%) received no treatment. Only 63% (41/65) of patients received curative-intent GCT as recommended with non-GCT associated with stage III (vs. stage II) disease (OR 0.10 CI (0.01-0.89)), HIV positivity ((OR 0.25 CI (0.06-0.99)) and hormone receptor (HR) negative/HER2 positive subtype ((OR 0.07 CI (0.01-0.49)). Curative-intent GCT was associated with improved OS (44.1 vs. 23.2 months; p = 0.00) compared to non-GCT.ConclusionWhile curative-intent GCT was associated with improved survival in this Malawian cohort, treatment completion rates were suboptimal. Resource-stratified guidelines must be paired with locally relevant, multilevel implementation strategies to target barriers to treatment completion.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer
    Sabatino, Susan A.
    Thompson, Trevor D.
    Wu, Xiao-Cheng
    Fleming, Steven T.
    Kimmick, Gretchen G.
    Trentham-Dietz, Amy
    Cress, Rosemary
    Anderson, Roger T.
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 146 (01) : 199 - 209
  • [2] Receipt of guideline-concordant care among young adult women with breast cancer
    White, Dolly P.
    Kurian, Allison W.
    Stevens, Jennifer L.
    Liu, Benmei
    Brest, Ariel E.
    Petkov, Valentina I.
    CANCER, 2021, 127 (18) : 3325 - 3333
  • [3] Does structural racism impact receipt of NCCN guideline-concordant breast cancer treatment?
    Lubarsky, Maya
    Hernandez, Alexandra E.
    Collie, Brianna L.
    Westrick, Ashly C.
    Thompson, Cheyenne
    Kesmodel, Susan B.
    Goel, Neha
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 206 (03) : 509 - 517
  • [4] Guideline-concordant treatment predicts survival: a National Cancer Database validation study of novel composite locoregional and systemic treatment scores among women with early stage breast cancer
    Tina W. F. Yen
    Zhuping Garacci
    Purushottam W. Laud
    Liliana E. Pezzin
    Ann B. Nattinger
    Breast Cancer, 2021, 28 : 698 - 709
  • [5] Guideline-concordant treatment predicts survival: a National Cancer Database validation study of novel composite locoregional and systemic treatment scores among women with early stage breast cancer
    Yen, Tina W. F.
    Garacci, Zhuping
    Laud, Purushottam W.
    Pezzin, Liliana E.
    Nattinger, Ann B.
    BREAST CANCER, 2021, 28 (03) : 698 - 709
  • [6] The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer
    Susan A. Sabatino
    Trevor D. Thompson
    Xiao-Cheng Wu
    Steven T. Fleming
    Gretchen G. Kimmick
    Amy Trentham-Dietz
    Rosemary Cress
    Roger T. Anderson
    Breast Cancer Research and Treatment, 2014, 146 : 199 - 209
  • [7] Association of Diabetes and Other Clinical and Sociodemographic Factors With Guideline-concordant Breast Cancer Treatment for Breast Cancer
    Gold, Heather T.
    Shao, Huibo
    Oratz, Ruth
    Yu, Onchee
    Hammer, Marilyn
    Richardson, Stephen
    Boudreau, Denise
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (02): : 101 - 106
  • [8] Association of guideline-concordant initial systemic treatment with clinical and economic outcomes among older women with metastatic breast cancer in the United States
    Vyas, Ami
    Mantaian, Tyler
    Kamat, Shweta
    Kurian, Sobha
    Kogut, Stephen
    JOURNAL OF GERIATRIC ONCOLOGY, 2021, 12 (07) : 1092 - 1099
  • [9] Guideline-Concordant Treatment Among Elderly Women With HER2-Positive Metastatic Breast Cancer in the United States
    Vyas, Ami M.
    Aroke, Hilary
    Kogut, Stephen
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (04): : 405 - +
  • [10] Receipt of Guideline-Concordant Treatment in Elderly Prostate Cancer Patients
    Chen, Ronald C.
    Carpenter, William R.
    Hendrix, Laura H.
    Bainbridge, John
    Wang, Andrew Z.
    Nielsen, Matthew E.
    Godley, Paul A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (02): : 332 - 338